Literature DB >> 30871356

Quality of Life Changes After Chronic Total Occlusion Angioplasty in Patients With Baseline Refractory Angina.

Taishi Hirai1,2, J Aaron Grantham1,2, James Sapontis3, David J Cohen1,2, Steven P Marso4, William Lombardi5, Dimitri Karmpaliotis6, Jeffrey Moses6, William J Nicholson7, Ashish Pershad8,9, R Michael Wyman10, Anthony Spaedy11, Stephen Cook12, Parag Doshi13, Robert Federici14, Karen Nugent1, Kensey L Gosch1, John A Spertus1,2, Adam C Salisbury1,2.   

Abstract

BACKGROUND: Health status and quality of life improvement after chronic total occlusion (CTO) percutaneous coronary intervention (PCI) among patients with refractory angina has not been reported. We sought to determine the degree of quality of life improvement after CTO PCI in patients with refractory angina. METHODS AND
RESULTS: Among 1000 consecutive patients who underwent CTO PCI in a 12-center registry, refractory angina was defined as any angina (baseline Seattle Angina Questionnaire [SAQ] Angina Frequency score of ≤90) despite treatment with ≥3 antianginal medications. Health status at baseline and 1-year follow-up was quantified using the SAQ. Refractory angina was present at baseline in 148 patients (14.8%). Technical success was achieved in 120 (81.1%) at the initial attempt and major adverse cardiac and cerebral events occurred in 10 (6.8%). There were no procedural deaths. Refractory angina patients were highly symptomatic at baseline with mean SAQ Angina Frequency of 51.1±23.8, SAQ quality of life of 35.3±21.2, and SAQ Summary Score of 47.2±17.9, improving by 32.0±27.8, 35.7±23.9, and 32.1±20.1 at 1 year. Through 1-year follow-up, patients with successful CTO PCI had significantly larger degree of improvement of SAQ Angina Frequency and SAQ Summary Score (35.0±26.8 versus 18.8±28.9, P<0.01; 34.2±19.4 versus 22.5±20.8, P<0.01) compared with unsuccessful CTO PCI.
CONCLUSIONS: Refractory angina was present in 1 of 7 patients in the OPEN-CTO (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures) registry. Patients with refractory angina experienced large, clinically significant health status improvements that persisted through 12 months, and patients with successful CTO PCI had larger health status improvement than those without.

Entities:  

Keywords:  chronic total occlusion; dyspnea; health status; percutaneous coronary intervention; quality of life; refractory angina; registry

Mesh:

Substances:

Year:  2019        PMID: 30871356     DOI: 10.1161/CIRCINTERVENTIONS.118.007558

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  5 in total

Review 1.  A contemporary review of clinical significances of percutaneous coronary intervention for chronic total occlusions, with some Japanese insights.

Authors:  Yoshihiro Morino
Journal:  Cardiovasc Interv Ther       Date:  2021-03-03

Review 2.  The Role of Multimodality Imaging for Percutaneous Coronary Intervention in Patients With Chronic Total Occlusions.

Authors:  Eleonora Melotti; Marta Belmonte; Carlo Gigante; Vincenzo Mallia; Saima Mushtaq; Edoardo Conte; Danilo Neglia; Gianluca Pontone; Carlos Collet; Jeroen Sonck; Luca Grancini; Antonio L Bartorelli; Daniele Andreini
Journal:  Front Cardiovasc Med       Date:  2022-05-02

3.  Clinical potential of angiogenic therapy and cellular reprogramming.

Authors:  Christopher T Ryan; Vivek Patel; Todd K Rosengart
Journal:  JTCVS Open       Date:  2021-03-18

4.  A Novel Classification for Predicting Chronic Total Occlusion Percutaneous Coronary Intervention.

Authors:  Dongfeng Zhang; Haoran Xing; Rui Wang; Jinfan Tian; Zhiguo Ju; Lijun Zhang; Hui Chen; Yi He; Xiantao Song
Journal:  Front Cardiovasc Med       Date:  2022-02-28

5.  The predictive value of the triglyceride-glucose index for cardiovascular events in patients with coronary chronic total occlusion.

Authors:  Yingkai Li; Songyuan He; Zheng Wu; Wenzheng Li; Wen Jian; Zichao Cheng; Cong Wang; Yuchen Shi; Jinghua Liu
Journal:  Cardiovasc Diabetol       Date:  2022-08-08       Impact factor: 8.949

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.